Welcome to our dedicated page for Lexeo Therapeutics SEC filings (Ticker: LXEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lexeo Therapeutics, Inc. (LXEO) SEC filings page on Stock Titan aggregates the company’s public regulatory documents from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret key disclosures. As a Nasdaq-listed, clinical stage genetic medicine company, Lexeo uses filings such as Forms 8-K, 10-Q, and 10-K to report material events, financial results, and risk factors related to its gene therapy programs and corporate activities.
In its 8-K filings, Lexeo has reported items such as quarterly financial results, equity financings through underwritten public offerings and concurrent private placements, material definitive agreements like underwriting and securities purchase agreements, and registration rights agreements related to pre-funded warrants. The company also uses 8-Ks to furnish press releases that provide interim clinical and regulatory updates for its lead programs, LX2006 in Friedreich ataxia (FA) cardiomyopathy and LX2020 in PKP2-associated arrhythmogenic cardiomyopathy.
Filings also describe Lexeo’s interactions with the FDA, including feedback on potential accelerated approval pathways, participation of LX2006 in the Chemistry, Manufacturing, and Controls Development and Readiness Pilot program, and regulatory designations such as Breakthrough Therapy, RMAT, Orphan Drug, Rare Pediatric Disease, and Fast Track. Corporate governance matters, executive appointments, compensation arrangements, and stockholder meeting results are likewise documented in SEC reports.
On Stock Titan, investors can review these filings alongside AI-generated highlights that summarize complex sections, helping to identify information on clinical development plans, capital structure changes, and other material disclosures. Real-time updates from EDGAR, combined with structured access to forms such as 10-K annual reports, 10-Q quarterly reports, and 8-K current reports, support deeper analysis of Lexeo’s regulatory and financial reporting history.
Lexeo Therapeutics Chief Operating Officer Jose Manuel Otero reported an open-market sale of 3,016 shares of common stock on February 18, 2026 at a weighted average price of $6.3972 per share. The sale was made to cover tax obligations on the release of restricted stock units. After this transaction, Otero beneficially owned 125,460 shares, including 104,216 restricted stock units.
Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan Townsend reported an open-market sale of 10,173 shares of common stock at a weighted average price of $6.382 per share. According to the footnotes, this sale was made to cover tax obligations on the release of restricted stock units. Following the transaction, he directly holds 392,483 shares, which include 261,349 restricted stock units.
Lexeo Therapeutics, Inc. Chief Operating Officer Jose Manuel Otero corrected a prior insider trade report and detailed a small tax-related sale of shares. An earlier Form 4 had mistakenly stated that a sale to cover tax obligations occurred on August 18, 2025. This amendment clarifies that the open-market sale of 721 shares of common stock actually took place on November 18, 2025 at a weighted average price of $9.27 per share, executed in multiple trades between $9.09 and $9.37. The sale was made solely to cover tax obligations from the release of restricted stock units. After this transaction, Otero directly owns 63,476 shares of Lexeo Therapeutics common stock, including 47,733 RSUs, so his overall stake in the company remains largely unchanged.
LXEO Form 144 filing reports planned resale of 11,374 common shares tied to restricted stock vesting. The filing lists a restricted stock vesting transaction dated
LXEO notice of proposed sale of
LXEO submitted a Form 144 reporting the proposed sale of 3,861 common shares tied to restricted stock vesting on 02/17/2026. The filing lists Fidelity Brokerage Services LLC as a broker/firm with a trade date of 02/18/2026 and indicates NASDAQ as the market.
LXEO reported a proposed sale of 3,736 common shares via Fidelity Brokerage Services following restricted stock vesting on
LXEO affiliate files to sell
The filing also discloses 615 shares sold during the prior three months (date
Lexeo Therapeutics’ Chief Medical Officer Narinder Pal Bhalla received new equity awards in the form of stock options and restricted stock units. On February 13, 2026, he was granted 297,000 stock options with a $6.31 exercise price and 49,500 RSUs, both at no cash cost to him.
The option grant vests with 25% of the underlying shares becoming exercisable on January 20, 2027, and the remaining 75% vesting in equal monthly installments over the following three years, contingent on continuous service. The RSUs vest 25% on February 15, 2027, with the rest vesting in equal quarterly installments thereafter, also subject to continued service.
Citadel-affiliated investment entities filed an amended Schedule 13G reporting beneficial ownership in Lexeo Therapeutics, Inc. common stock. The filing states that Kenneth Griffin may be deemed to beneficially own 5,498,219 Shares, representing 7.4% of Lexeo’s outstanding common stock.
Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may each be deemed to beneficially own 5,405,269 Shares, or 7.2% of the class, while certain Citadel Securities entities report smaller positions of 6,600 and 92,950 Shares. The percentages are based on 74,704,629 Shares outstanding, including 1,717,302 Shares issuable upon warrant conversion. The reporting persons certify the securities are not held to change or influence control of Lexeo.